# A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers

> **NCT02920931** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 50 (actual)

## Conditions studied

- Hepatitis

## Interventions

- **DRUG:** Tenofovir disoproxil

## Key facts

- **NCT ID:** NCT02920931
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920931, "A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02920931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*